We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
12 Aug 2021 - 14 Aug 2021
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Personal ECG Device Measures QTc Interval Prolongation

By HospiMedica International staff writers
Posted on 20 Jul 2021
Print article
Image: The KardiaMobile 6L in acquisition position (Photo courtesy of AliveCor)
Image: The KardiaMobile 6L in acquisition position (Photo courtesy of AliveCor)
A non-invasive, hand-held electrocardiogram (ECG) device allows manual QTc interval measurement, an important measure of pharmaceutical side effects.

The AliveCor (San Francisco, CA, USA) KardiaMobile 6L is a six-lead personal ECG device that can detect various arrhythmias by simulating the Einthoven Triangle, an ECG that is taken by placing leads on three limbs (both arms and a leg), thus placing the heart at the center. The result is six different perspectives that are equivalent to leads I, II, II, aVL, aVR, and aVF on a 12-lead ECG. In order to obtain an ECG, users place their thumbs on each of the top-side electrodes and place the bottom electrode on the left knee or the ankle.

Unlike most personal ECGs, such as smartwatches, the KardiaMobile 6L also records lead II data, which provides a far more accurate view of the QTc interval than the lead I view. The KardiaMobile 6L can thus detect atrial fibrillation (AF), bradycardia, tachycardia, QTc, and others measures over a period of just 30 seconds. In order to view the ECG, KardiaMobile 6L is paired via Bluetooth with a smartphone or tablet, and the data is sent to the Kardia app for instant analysis.

“Patient safety is paramount, and this is why we are proud to offer physicians the ability to monitor QTc through the convenience and quality of our device,” said Priya Abani, CEO of AliveCor. “Our aim is to help reduce the burden on our already strained healthcare system, so that clinicians can focus on treating patients. By delivering this service, we are doing just that.”

QTc is a heart rate corrected interval that reflects the integrity of the heart's electrical recharging system. Patients with a prolonged QTc are at greater risk for their hearts to go into a potentially dangerous arrhythmia called Torsades de Pointes, which can lead to sudden cardiac arrest (SCA). More commonly, QT prolongation is a potential side effect of more than 100 drugs, including certain antiarrhythmic medicines, cancer therapies, antifungals, antipsychotics, antidepressants, antibiotics, multiple sclerosis (MS) medications, and opioids.

Related Links:
AliveCor


Print article

Channels

Business

view channel
Image: BD Seeks to Transform Patient Experience Through Vision of `One-Stick Hospital Stay` (Photo courtesy of BD)

BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.